Baird Downgrades Surface Oncology to Neutral
Portfolio Pulse from richadhand@benzinga.com
Baird analyst Colleen Kusy downgrades Surface Oncology (NASDAQ:SURF) from Outperform to Neutral.

June 20, 2023 | 11:26 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Surface Oncology (NASDAQ:SURF) has been downgraded from Outperform to Neutral by Baird analyst Colleen Kusy.
The downgrade from Outperform to Neutral by Baird analyst Colleen Kusy indicates a change in the outlook for Surface Oncology. This could lead to a short-term negative impact on the stock price as investors may adjust their positions based on the new rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100